Skip to content
OpenCapital
Get started

Pacific Biosciences of California PACB Investment Income Net Amortization Of Discount And Premium

Investment Income Net Amortization Of Discount And Premium at other companies

Azenta logo
AzentaAZTA
$308K-30.3%

Other financials

Income statement

See full
Revenue$37.2M+0.1%
Gross profit$12.8M+1,037%
Operating income-$8.4M+98.1%
Net income-$8.3M+98.1%
EPS (diluted)-$0.03+97.9%

Balance sheet

See full
Cash & equivalents$57.9M-4.7%
Total debt$59.3M+12.1%
Total equity$2.4M-97.4%
Total assets$782.4M-9.1%

Cash flow

See full
Operating cash flow-$44.7M-1.4%
CapEx$3.0M+119%
Free cash flow-$47.7M-5.0%

Valuation

See full
Market cap$496.96M+30.4%
Enterprise value$498.38M+33.5%
P/S3.1×+0.6×

Profitability

See full
Gross margin37.5%+21.3pp
Operating margin-83.3%-38.2pp
Net margin-80.3%-36.1pp
FCF margin-72.6%-20.0pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's investment income net amortization of discount and premium.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacific Biosciences of California's investment income net amortization of discount and premium?
Pacific Biosciences of California (PACB) reported investment income net amortization of discount and premium of $295K in Q1 2026.
How has Pacific Biosciences of California's investment income net amortization of discount and premium changed year-over-year?
Pacific Biosciences of California's investment income net amortization of discount and premium decreased by 82.7% year-over-year, from $1.71M to $295K.
What is the long-term trend for Pacific Biosciences of California's investment income net amortization of discount and premium?
Over 4 years (2021 to 2025), Pacific Biosciences of California's investment income net amortization of discount and premium has grown at a 2.1% compound annual growth rate (CAGR), from -$4.01M to $4.37M.
What does investment income net amortization of discount and premium mean?
Captures the net impact of interest income earned on investments and the non-cash amortization of premiums or discounts on those securities. It reflects the yield generated from the company's cash and investment portfolio.